Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX310 · 1 trial · 10 indications
Incidence of dose-limiting toxicities and frequency of adverse events
| Arm | Type | Description |
|---|---|---|
| CTX310 | EXPERIMENTAL | Subjects will receive an intravenous (IV) infusion. |
| Name | Type | Description |
|---|---|---|
| CTX310 | DRUG | CTX310 is a lipid nanoparticle (LNP) formulation of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) components for in vivo editing of the target gene angiopoietin-like 3 (ANGPTL3). |
Key Inclusion Criteria: 1. Age of ≥18 and ≤75 years at the time of signing the informed consent. 2. Able to provide written informed consent. 3. Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg/dL - and LDL-C ≥70 mg/dL in participants with ASCVD, or LDL-C ≥70 or 100mg/dL i...